Welcome

Welcome to the Investor Relations section of Vitruvia. This area is dedicated to keeping shareholders and potential investors up to date with relevant information on Vitruvia and its shares.

Press releases


New cooperation of LT technologies GmbH & Co. KG with TRES MEDICO, Malaysia

Our affiliate LT technologies has entered a cooperation in the field of repair service with the…

Successful certification of FFP 2 masks with medical approval of LT technologies

LT technologies has successfully passed the certification of the FFP2 masks with medical approval.

Vitruvia Medical AG reports first-half 2021 results in line with expectations. Board of Directors confirms full-year and 2022 forecasts

Anglikon, September 13, 2021 Vitruvia Medical AG is right on target after the first six months of…

Ad-hoc News


Consolidated inter results as per June 30th, 2023

Vitruvia Medical AG achieves results as expected in the first half of 2023. The Board of Directors…

Annual results as of 31.12.2022 and outlook 2023

Vitruvia Medical AG reported net income after taxes of CHF -1,095,349.38 for the year ended…

Vitruvia Medical AG has carried out an authorised capital increase

Vitruvia Medical AG has carried out an authorised capital increase as of today.

Key performance indicatorsVitruvia Medical AG share

NameWerte
Number of sharesThe share capital is CHF 2'511'578.00 and is divided into 2'511'578 registered shares, each with a nominal value of CHF 1.00
WKNA2PDWF
ISINCH0461931419
ValorCH046193141
Availability of sharesAll registered shares are freely transferable.
End of fiscal yearDecember 31
Stock exchangeMunich Stock Exchange
Market segmentGeneral open market
Initial listingMay 11, 2021

Course data

NameWerte
Current share price (Link to Munich Stock Exchange)
52-Week-HighEUR 11,50
52-Week-LowEUR 1,00

Your contact

Markus A. Bertschin
President of the Board of Directors

T +41 (0)44 915 33 78
M +41 (0)79 233 26 09
bertschin@vitruvia-med.com

Vitruvia Medical AG
Kesselackerstrasse 18
5611 Anglikon I Switzerland